ArticlePloS one2021
Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05565976. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
Who cites it
12 citing papers in PubMed.
- Carotid Atherosclerosis in Chronic Kidney Disease: Pathophysiological Mechanisms, Prevention and Tailored Clinical Management.Journal of clinical medicine · 2026Review
- Segmentation and morphometry of intracranial internal carotid artery calcification in relation to brain atrophy.Neuroradiology · 2026Article
- Association between hemoglobin glycation index and carotid plaques in non-dialysis CKD stage 3-5 patients: a retrospective cross-sectional study.International urology and nephrology · 2026Article
- Carotid plaque number and length as predictors of coronary heart disease in patients with early-stage chronic kidney disease.Frontiers in cardiovascular medicine · 2026Article
- Serum midkine level and its association with subclinical coronary artery calcification and carotid atherosclerosis in chronic kidney disease.BMC nephrology · 2025Article
- Carotid plaque thickness predicts cardiovascular events and death in patients with chronic kidney disease.BMC nephrology · 2024Article
- The role of aetiology in cardiac manifestations of chronic kidney disease: the CPH-CKD ECHO study.The international journal of cardiovascular imaging · 2024Article
- Clinicopathological characteristics and predictors of outcome of rapidly progressive glomerulonephritis: a retrospective study.BMC nephrology · 2024Article
- The Associations Between Abdominal Obesity and Coronary Artery Calcification in Chronic Kidney Disease Population.International journal of nephrology and renovascular disease · 2024Article
- Plasma activin A rises with declining kidney function and is independently associated with mortality in patients with chronic kidney disease.Clinical kidney journal · 2023Article
- The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque.BMC cardiovascular disorders · 2023Article
- Left ventricular structure and function in patients with chronic kidney disease assessed by 3D echocardiography: the CPH-CKD ECHO study.The international journal of cardiovascular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease accelerates both atherosclerosis and arterial calcification. The aim of the present study was to explore whether maximal carotid plaque thickness (cPTmax) was increased in patients with chronic kidney disease compared to controls and associated with cardiovascular disease and severity of calcification in the carotid and coronary arteries.
methodsThe study group consisted of 200 patients with chronic kidney disease stage 3 from the Copenhagen Chronic Kidney Disease Cohort and 121 age- and sex-matched controls. cPTmax was assessed by ultrasound and arterial calcification by computed tomography scanning.
resultsCarotid plaques were present in 58% of patients (n = 115) compared with 40% of controls (n = 48), p = 0.002. Among participants with plaques, cPTmax (median, interquartile range) was significantly higher in patients compared with controls (1.9 (1.4-2.3) versus 1.5 (1.2-1.8) mm), p = 0.001. Cardiovascular disease was present in 9% of patients without plaques (n = 85), 23% of patients with cPTmax 1.0-1.9 mm (n = 69) and 35% of patients with cPTmax >1.9 mm (n = 46), p = 0.001. Carotid and coronary calcium scores >400 were present in 0% and 4%, respectively, of patients with no carotid plaques, in 19% and 24% of patients with cPTmax 1.0-1.9 mm, and in 48% and 53% of patients with cPTmax >1.9 mm, p<0.001.
conclusionsThis is the first study showing that cPTmax is increased in patients with chronic kidney disease stage 3 compared to controls and closely associated with prevalent cardiovascular disease and severity of calcification in both the carotid and coronary arteries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.